You are here: Home / Biomarkers / Mitochondrial Genome Deletion for Detection of Prostate Cancer

Mitochondrial Genome Deletion for Detection of Prostate Cancer


This biomarker is also known as:
  • Prostate Core Mitomic Test™,
  • Mitochondrial deletion for detection of prostate cancer,


The Prostate Core Mitomic Test™ is based upon a 3.4 kb mitochondrial genome deletion (3.4 mtdelta) that was identified through PCR analysis of frozen prostate cancer samples. In cancer research it has been found that deletions in mitochondrial DNA can correlate with cellular changes that indicate development of cancer. This deletion includes the terminal 22 bases of MT-ND4L, all of MT-ND4, 3 tRNAs (histidine, serine 2, and leucine 2), and all except the terminal 24 bases of MT-ND5.


QA State: Curated
Type: Genomic
Short Name:
HGNC Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Three
QA State: Curated


Mitochondrial DNA deletions are known to be associated with many cancers. This 3.4 kb deletion was found to be specific to prostate cancer.

Performance Comment

Both pilot and confirmation studies demonstrated that this 3.4 kb mitochondrial deletion is a highly significant biomarker for prostate cancer. In the pilot study the difference between benign and malignant core biopsy samples was P > .0001. Results from the larger study were identical. In a blinded external validation study, sensitivity was 83% and specificity was 79%. The area under the ROC curve was 0.87 for the deletion.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


No associated Biomuta entries found.

This icon signifies that something is happening and we kindly ask you to please wait